SynthesisThe Cochrane database of systematic reviews2010
Angiogenesis-inhibitors for metastatic thyroid cancer.
Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.The Cochrane database of systematic reviews · 2021Pooled it
- Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report.Frontiers in oncology · 2026Article
- EDIL3 induced by GLIS2 suppresses the anti-tumor activity of CD8Journal of molecular histology · 2025Article
- Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.Frontiers in endocrinology · 2024Review
- Anti(angiogenic) food components: can be a major source of bias in the investigation of angiogenesis inhibitors.Annals of translational medicine · 2023Review
- Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study.BMC cancer · 2023Article
- Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.Frontiers in endocrinology · 2022Review
- Molecular testing in the diagnosis of differentiated thyroid carcinomas.Gland surgery · 2018Review
- CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.Disease markers · 2018Article
- Molecular Targeted Therapies of Aggressive Thyroid Cancer.Frontiers in endocrinology · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic cytostatic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. Tumor growth and metastasis depend on blood supply and blood vessel formation (angiogenesis). Therefore, inhibition of angiogenesis may represent a promising target for cancer therapy.
objectivesTo evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination with chemotherapy or radiotherapy. SEARCH STRATEGY: We searched The Cochrane Library (2009, Issue 2), MEDLINE (January 2000 to May 2009) and EMBASE (January 2000 to May 2009) databases and abstracts published in annual proceedings for evidence. Attempts were made to identify studies from references in potentially relevant trials. We also searched for ongoing trials. SELECTION CRITERIA: We planned to include randomized controlled trials that compared angiogenesis-inhibitors with other treatments, no treatment, or placebo in participants who had pathologically confirmed advanced thyroid cancer. DATA COLLECTION AND ANALYSIS: Two authors independently evaluated the search results against the selection criteria. Data extraction and risk of bias assessment were not performed because there were no studies that could be included. MAIN
resultsWe did not identify any studies which met our full inclusion criteria. AUTHORS'
conclusionsThere is currently no reliable evidence available from randomized controlled trials regarding the bene fi ts and harms of the use of angiogenesis-inhibitors for treating advanced thyroid cancer. Several trials are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.